Dr. Reddy’s Laboratories (DRREDDY) Share Price Fall Streak: Second Straight Session, Rs 1,207.80
- October 1, 2026
- Posted by: Kunal Singla
- Category: News
Dr. Reddy’s Laboratories Share Price Fall Streak has now stretched into a second straight session, with the stock trading at Rs 1,207.80 after a cumulative fall of 3.38% from the streak start base price of Rs 1,250. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established. Dr. Reddy’s Laboratories Share Price Fall Streak is therefore being read mainly through the lens of repeated lower closes rather than a one-off intraday move.
The company’s market capitalisation stands at Rs 1,04,335.04 crore, which keeps the focus on how a large-cap healthcare name is being valued after two lower sessions. For readers tracking Dr. Reddy’s Laboratories Share Price Fall Streak, the key difference versus a single-day decline is that the move now reflects continuity across sessions, not just a temporary dip. That makes the valuation read, sector comparison and peer positioning more relevant in Dr. Reddy’s Laboratories Share Price Fall Streak discussion.
Dr. Reddy's Laboratories (DRREDDY) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,207.8 |
| Previous Close | Rs 1,236 |
| Today's Move | -Rs 28.20 (-2.28%) |
| Open | Rs 1,216.1 |
| High | Rs 1,241.3 |
| Low | Rs 1,206.9 |
| Market Capitalisation | Rs 1,04,335.04 crore |
Dr. Reddy’s Laboratories Share Price opened at Rs 1,216.10, touched a high of Rs 1,241.30 and a low of Rs 1,206.90, before last trading at Rs 1,207.80. The previous close was Rs 1,236, so the stock was down Rs 28.20, or 2.28%, at the time of this update. In the context of Dr. Reddy’s Laboratories Share Price Fall Streak, that means the second straight session has again finished below the prior session’s reference level.
The low of Rs 1,206.90 shows that the share price moved very close to the session floor before the latest update, while the high of Rs 1,241.30 marked the upper end of the range. The company’s market capitalisation remained Rs 1,04,335.04 crore, placing Dr. Reddy’s Laboratories Share Price Fall Streak inside the Large Cap universe. For readers following Dr. Reddy’s Laboratories Share Price Today, the main point is simple: the price has remained under the previous close and the two-session pattern is now visible in the intraday range too.
That session profile is important because Dr. Reddy’s Laboratories Share Price Fall Streak is no longer just a single lower print. The current move should be read alongside the next section on fundamentals, where the valuation base has to be judged after the cumulative decline.
What the Consecutive Declines Show
Dr. Reddy’s Laboratories Share Price Fall Streak is now a second straight session lower, and the cumulative move since the streak started is -3.38%. The base price for that run was Rs 1,250, so the latest price remains below that starting point by a noticeable margin. According to latest Univest figures, the same earnings and book-value base is being priced at a lower share price now than at the start of the streak.
For a reader, the difference between a one-day fall and a two-session decline matters because the latter shows persistence in price behaviour. Dr. Reddy’s Laboratories Share Price Fall Streak therefore deserves attention as a pattern, not as an isolated candle. The latest Univest data confirms the lower-close sequence; it does not establish a company-specific cause for the continued move. That keeps the analysis anchored in facts rather than assumptions.
In practical terms, Dr. Reddy’s Laboratories Share Price Fall Streak suggests that the market is still re-rating the stock downward across consecutive sessions, while the next fundamental and sector sections help place that move in context.
Dr. Reddy's Laboratories (DRREDDY) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,04,335.04 crore |
| P/E Ratio | 32.02x |
| P/B Ratio | 2.7x |
| ROE | 11.69% |
| ROCE | 13.75% |
| EPS | Rs 38.6 |
| Book Value Per Share | Rs 457.39 |
| Dividend Yield | 0.65% |
Dr. Reddy's Laboratories (DRREDDY) fundamental metrics show P/E 32.02x, P/B 2.7x, ROE 11.69%, ROCE 13.75%. These figures provide context only and are not a buy or sell signal.
Dr. Reddy’s Laboratories has a market capitalisation of Rs 1,04,335.04 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 32.02x, P/B at 2.7x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.69% and ROCE of 13.75%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 38.6, book value per share of Rs 457.39, dividend yield of 0.65%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.02x, median ROE of 11.7%, median ROCE of 13.61%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 32.02x |
| Benchmark Median P/E | 32.02x |
| Benchmark Average P/E | 49.17x |
| Benchmark P/E Range | 3.4x to 688.17x |
| Company P/B Ratio | 2.7x |
| Benchmark Median P/B | 2.94x |
| Benchmark Average P/B | 4.37x |
| Company ROE | 11.69% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 13.75% |
| Benchmark Median ROCE | 13.61% |
| Benchmark Average ROCE | 13.4% |
| Company Market Capitalisation | Rs 1,04,335.04 crore |
| Benchmark Median Market Cap | Rs 770.9 crore |
| Benchmark Average Market Cap | Rs 14,358.25 crore |
Dr. Reddy's Laboratories (DRREDDY) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Dr. Reddy's Laboratories (DRREDDY) has a P/E ratio of 32.02x, which is equal to the benchmark median of 32.02x, a difference of 0%. On its own, the P/E gap is a valuation reference point, not a trading call.
Dr. Reddy's Laboratories (DRREDDY) has a ROE of 11.69%, which is below the benchmark median of 11.7%, a difference of -0.09%. Dr. Reddy's Laboratories (DRREDDY) has a ROCE of 13.75%, which is above the benchmark median of 13.61%, a difference of +1.03%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,46,276.3 | 36.1 | 5.05 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,51,531.48 | 84.24 | 13.95 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,86,956.51 | 83.74 | 20.35 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,19,221.66 | 25.71 | 4.3 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,728.51 | 32.36 | 3.1 | 11.83 | 16 |
Dr. Reddy's Laboratories (DRREDDY) has a P/E ratio of 32.02x compared with the displayed peer median of 36.1x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 11.69% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 13.75% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Dr. Reddy's Laboratories (DRREDDY) has a market capitalisation of Rs 1,04,335.04 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Dr. Reddy’s Laboratories
- Dr. Reddy’s Laboratories Share Price Fall Streak has extended to a second straight session, so the price pattern is now more than a one-day move.
- The current price of Rs 1,207.80 is below the streak start base price of Rs 1,250, keeping the cumulative change in focus.
- P/E at 32.02 and P/B at 2.7 place the stock near the benchmark median on one metric and slightly below it on the other.
- ROE of 11.69% and ROCE of 13.75% give a clear profitability and capital-efficiency backdrop for Dr. Reddy’s Laboratories Share Price Fall Streak.
- The company remains a Large Cap name in Healthcare, so the move is being watched within a major industry benchmark rather than in isolation.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories operates in Healthcare and the Pharmaceuticals & Drugs industry. The business context needed for Dr. Reddy’s Laboratories Share Price Fall Streak is straightforward: it is a large pharmaceutical company whose valuation is still shaped by earnings, book value and capital returns rather than by a single-session price move. Dr. Reddy’s Laboratories Share Price Fall Streak therefore matters because the stock is being repriced inside a mature sector where peers are also evaluated closely on profitability and valuation.
For investors reading Dr. Reddy’s Laboratories Share Price Fall Streak, the key business point is that the company belongs to a sector where the market typically tracks P/E, P/B, ROE and ROCE closely. That makes the current decline more useful as a valuation signal than as a standalone headline.
Track Dr. Reddy’s Laboratories Share Price on Univest
Use Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Readers can track Dr. Reddy’s Laboratories Share Price Fall Streak alongside live share price movements, fundamental ratios, 52-week levels and market insights on Univest. The same page also helps place Dr. Reddy’s Laboratories Share Price in context with market capitalisation, profitability ratios and peer positioning. For anyone following Dr. Reddy’s Laboratories Share Price Fall Streak, this creates a single place to monitor the price action and the underlying numbers together.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Dr. Reddy's Laboratories Share Price falling today?
Ans. Dr. Reddy's Laboratories Share Price is lower today because the stock is in a second straight session of decline. According to Univest data, the price event is confirmed, but no company-specific catalyst is established.
What is Dr. Reddy's Laboratories Share Price today?
Ans. Dr. Reddy's Laboratories Share Price was Rs 1,207.80 at the latest update. It was down Rs 28.20, or 2.28%, from the previous close of Rs 1,236. The intraday range extended from Rs 1,206.9 to Rs 1,241.3.
What does the second straight session mean for Dr. Reddy's Laboratories Share Price?
Ans. The second straight session means the stock has now closed lower on two consecutive trading days. Dr. Reddy's Laboratories Share Price Fall Streak is therefore a short pattern, not just a one-day move.
How much has Dr. Reddy's Laboratories Share Price fallen in the streak?
Ans. Dr. Reddy's Laboratories Share Price Fall Streak has a cumulative decline of 3.38% from the starting base price of Rs 1,250. The latest price remains below that streak base. The previous close was Rs 1,236.
What is the market capitalisation of Dr. Reddy's Laboratories?
Ans. Dr. Reddy's Laboratories has a market capitalisation of Rs 1,04,335.04 crore. That keeps the company in the Large Cap bracket and gives the share price move a major-cap context. The company operates in the Healthcare sector.
How do Dr. Reddy's Laboratories valuation ratios compare with the sector?
Ans. The stock trades at a P/E of 32.02 and a P/B of 2.7. P/E matches the benchmark median, while P/B is slightly below the benchmark median of 2.94 in Healthcare.
What do ROE and ROCE show for Dr. Reddy's Laboratories?
Ans. ROE stands at 11.69% and ROCE at 13.75%. Those levels are close to or slightly above the sector median in the benchmark set, showing moderate return generation against peers. The relevant peer median ROE is 11.7%.
Should investors track Dr. Reddy's Laboratories Share Price on Univest?
Ans. Yes, because Dr. Reddy's Laboratories Share Price Fall Streak links price action with valuation and sector context. Univest also tracks the share price with fundamental ratios, 52-week levels and peer comparison in one place.
